Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases.

导出 OA

翻译打印收藏纠错

作者： Teresa Po-Yu,Chiang ^[1] ; Caoilfhionn M,Connolly ^[2] ; Jake A,Ruddy ^[1] ; Brian J,Boyarsky ^[1] ; Jennifer L,Alejo ^[1] ; William A,Werbel ^[3] ; Allan,Massie ^[1] ; Lisa,Christopher-Stine ^[2] ; Jacqueline,Garonzik-Wang ^[1] ; Dorry L,Segev ^[4] ; Julie J,Paik ^[5]

作者单位： Department of Surgery, Johns Hopkins University, Baltimore, Maryland, USA. ^[1] Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA. ^[2] Department of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA. ^[3] Department of Surgery, Johns Hopkins University, Baltimore, Maryland, USA dorry@jhmi.edu. ^[4] Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. ^[5]

关键词 COVID-19 antirheumatic agents autoimmune diseases epidemiology vaccination

主题词抗体生成(Antibody Formation);人类(Humans);肌骨骼疾病(Musculoskeletal Diseases)

DOI 10.1136/annrheumdis-2021-221145

PMID 34429320

发布时间 2021-10-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交